scholarly journals Malaria: What does the RTS,S/AS01 Vaccine Mean for Children in Africa?

2021 ◽  
pp. 1-6
Author(s):  
Andrew Macnab ◽  
Keyword(s):  
Quality Of Life ◽  
Infectious Disease ◽  
Economic Productivity ◽  
Resource Poor ◽  
Educational Potential

Malaria is an example of an infectious disease which if not diagnosed appropriately and treated promptly can devastate the life of a child. Globally it also has a major impact on quality of life, educational potential, and economic productivity, particularly in resource-poor settings.

scholarly journals IMMUNIZATION AS A HEALTHY AGING STRATEGY

2019 ◽  
Vol 3 (Supplement_1) ◽  
pp. S212-S212
Author(s):  
Eduardo De Gomensoro
Keyword(s):  
Quality Of Life ◽  
Infectious Disease ◽  
Older Adults ◽  
Disease Prevention ◽  
Healthy Aging ◽  
Lifestyle Modification ◽  
Provider Education ◽  
Life Issues ◽  
Children Under 5

Abstract The burden of infectious disease is heavier at the extremes of life: the youngest and the oldest typically have the highest incidence of infectious diseases along with morbidity and mortality. Demographic studies show by the next decade, adults over 65 will outnumber children under 5 years of age. Unfortunately, vaccination coverage in older adults even where permissive recommendations exist is universally lower than in infants or children. Key reasons are a lack of knowledge and understanding of the benefits of vaccination, and inconsistent recommendations by providers. Recently, the concept of ‘healthy aging’ – regular vaccination and lifestyle modification including exercise and diet – has been proposed to go beyond disease prevention and address quality of life issues such as the ability to remain in work, and to live independently. Public and healthcare provider education to ascertain the value of older adult’s immunization are critical for the fulfilment of this agenda.

scholarly journals Multivitamin supplementation in HIV-positive pregnant women: impact on depression and quality of life in a resource-poor setting

HIV Medicine ◽  
2007 ◽  
Vol 8 (4) ◽  
pp. 203-212 ◽  
Author(s):  
MC Smith Fawzi ◽  
SF Kaaya ◽  
J Mbwambo ◽  
GI Msamanga ◽  
G Antelman ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Pregnant Women ◽  
Resource Poor Setting ◽  
Hiv Positive ◽  
Multivitamin Supplementation ◽  
Resource Poor

scholarly journals Successful treatment of dysphagia in a COVID-19 survivor

2021 ◽  
Vol 7 (10) ◽  
pp. 509
Author(s):  
Richa Rashmi ◽  
Joyanta C. Mandal ◽  
Kavita Kumari ◽  
Shruti S. Senapati
Keyword(s):  
Quality Of Life ◽  
Infectious Disease ◽  
Respiratory Compromise ◽  
Swallowing Therapy ◽  
Effortful Swallow ◽  
Successful Case ◽  
Icu Discharge ◽  
Swallowing Difficulty ◽  
Management Of Dysphagia

<p class="abstract">This study was aimed<strong> </strong>document a successful case of dysphagia management after coronavirus disease 2019 (COVID-19) infection. COVID-19 is highly infectious disease and causes 75 million infection and 1.66 million deaths worldwide. Clinical features of COVID-19 including respiratory compromise, microvascular thrombosis and neurologic dysfunction as well as well as prolonged intensive care unit (ICU) care in severe cases yield patients particularly susceptible to mild to severe swallowing impairment which can persist for months or years after ICU discharge. A 52 years old female was diagnosed with severe pharyngo-oesophageal dysphagia after COVID-19 infection and was advised for swallowing therapy. The swallowing therapy was given thrice a week for 45 minutes including Masako, Shaker’s and modified Shaker’s exercise along with effortful swallow, Mendelsohn maneuvers and super-supraglottic swallow. After 2 weeks of swallowing therapy patient started taking semisolid food orally and maintain normal SpO<sub>2 </sub>level during feeding. This study concluded early intervention is the key to boost faster recovery and helped to improve patient’s quality of life.<strong> </strong>Swallowing manuvers and exercises were very effective for the management of dysphagia secondary to COVID-19 infection. This can be generalized and efficacy can be determined with large group of patients having swallowing difficulty after COVID-19 infection.</p>

scholarly journals HIV, Homosexuality and Depression – Challenges at Primary Care: A Case Report

2020 ◽  
Vol 4 (2) ◽  
pp. 145
Author(s):  
Fadzilah Mohamad ◽  
Lee Ping Yein ◽  
Maliza Mawardi
Keyword(s):  
Quality Of Life ◽  
Infectious Disease ◽  
Primary Care ◽  
Case Report ◽  
Health Sciences ◽  
Major Depressive ◽  
Immunodeficiency Virus ◽  
Negative Impacts ◽  
Sex With Men

Human Immunodeficiency Virus (HIV) is a chronic lifelong infectious disease that greatly impairs the quality of life. HIV and men who have sex with men (MSM) are seen to be synonyms to each other and both were shown to be the risks for depression. This case report is about a homosexual man who contracted HIV via the MSM activity. Being both homosexual and HIV-infected had given him a lot of negative impacts, stigma and discrimination, which drove him into having major depressive disorder. Having depression with underlying HIV and homosexuality has made this case complicated and challenging, especially when it has to be managed at the primary care level.International Journal of Human and Health Sciences Vol. 04 No. 02 April’20 Page : 145-147

scholarly journals Changes And Future Challenges In The Disease Burden of Inpatients Living With HIV In China: A Predictive Study Based On Retrospective Cohort Data

2021 ◽  
Author(s):  
Yong Shuai ◽  
Jingmin Nie ◽  
Yinqiu Huang ◽  
Yaokai Chen
Keyword(s):  
Neural Network ◽  
Quality Of Life ◽  
Infectious Disease ◽  
Metabolic Syndrome ◽  
Disease Burden ◽  
Opportunistic Infections ◽  
Age Groups ◽  
People Living With Hiv ◽  
Living With Hiv

Abstract Objective: In China, the widespread use of Combination Antiretroviral Therapy (cART) has significantly improved the prognosis and quality of life in people living with HIV(PLWH). However, some PLWH still got worse and were hospitalized for some reasons, including AIDS-Defining Diseases(AD, such as opportunistic infections and AIDS-related Malignancies), Non-AIDS-Defining Diseases (NAD, such as non-AIDS-defining Malignancies and metabolic syndrome). At present, the age and disease of inpatients living with HIV(ILWH) are undergoing some significant changes. For example, the average age of ILWH is gradually increasing, the proportions of ILWH with NAD in all age groups are increasing, and the proportion of ILWH suffering from multiple types of NAD is increasing, which will have a greater impact to both ILWH and infectious disease hospitals. We aim to predict the changes in ILWH in the next 10 years, analyze the impact of such changes on ILWH and infectious disease hospitals in China, and propose corresponding countermeasures.Methods: Based on the 12618 data of ILWH admitted to Chongqing Public Health Medical Center during 2010-2020, We have established a long- and short-term time-series network (LSTNet) deep learning framework based on the Convolution Neural Network (CNN) and the Recurrent Neural Network (RNN). By the framework, we have predicted the age, the proportion of AD and NAD , the proportion of multiple NADs, and the proportion of NAD occurrences in ILWH up to 2030 .Results: Our model showed that the average age of ILWH has risen from 43.8 years in 2010 to 57.6 years in 2030, and the increase in the age of women is greater than that of men. The number of ILWH in different age groups has changed significantly. Among them, the proportion of ILWH under 50 years old has gradually decreased, and the proportion of ILWH over 50 years old has gradually raised. By 2030, the proportion of ILWH over 50 years old will be close to 80%. The proportion of fatal opportunistic infections among ILWH has decreased year by year, and the most common diseases are tuberculosis-related diseases. The proportions of ILWH with only AD or NAD have gradually decreased, and the proportion of ILWH with both AD and NAD has increased year by year. It is estimated that the proportion of all ILWH with both AD and NAD will exceed 80% by 2030. Among all kinds of diseases in NAD, metabolic syndrome will have the highest rate of increase. By 2030, it will account for 16% in all ILWH. The proportion of hepatobiliary and pancreatic system diseases and blood system diseases in NAD will gradually decrease, while the proportion of metabolic syndrome, kidney disease, gastrointestinal disease, non-AIDS defining malignancies(NADM), bone disease and neurological diseases in NAD will gradually increase. The proportion of ILWH with NAD in all age groups will increase significantly after 10 years. Among them, the proportion of ILWH with NAD in 50-60 years old will be more than 80%, and among the ILWH under 30 years old, the proportion of ILWH suffering from NAD will increase to 69.6%. The proportion of ILWH without NAD or only 1 NAD will decrease, while the proportion of ILWH with 3 or more NAD will rise sharply. The proportion of ILWH with 1 type of NAD will drop to 12.6%, while the proportion of ILWH with 2 types of NAD, and the proportion of ILWH with 3 or more types of NAD will increase greatly.Conclusions: Significant changes have took place in the disease burden of ILWH in China, including the aging, the increase in the proportion of ILWH with NAD, and the increase in the proportion of ILWH with multiple types of NAD. These changes mean that in the next 10 years, the diagnosis, treatment and care of ILWH, as well as the development and construction of infectious disease hospitals will all face new challenges. This finding is based on a large number of long-term ILWH data in Chongqing, China, so we can consider that our research strategy can be promoted in China to improve the cure rate and quality of life in ILWH.

Assessing the Quality of Life of Patients with Breast Cancer Treated in a Tertiary Hospital in a Resource-Poor Country

2018 ◽  
Vol 43 (1) ◽  
pp. 44-51 ◽  
Author(s):  
Chinedu Okoli ◽  
S. N. C. Anyanwu ◽  
Amobi O. Ochomma ◽  
Chiemelu D. Emegoakor ◽  
Gabriel U. Chianakwana ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Quality Of Life ◽  
Poor Country ◽  
Tertiary Hospital ◽  
Resource Poor Country ◽  
Resource Poor

Infectious Disease Concepts and Considerations in the Diabetic Patient

2009 ◽  
Vol 22 (6) ◽  
pp. 571-574
Author(s):  
Michael D. Schwartz ◽  
Scott E. Kincaid
Keyword(s):  
Quality Of Life ◽  
Infectious Disease ◽  
Invasive Disease ◽  
Diabetic Patients ◽  
Targeted Prevention ◽  
Aggressive Treatment ◽  
Prevention And Treatment ◽  
Disease Concepts

Diabetic patients present their providers with unique clinical challenges when dealing with prevention and treatment of infectious diseases. By the very nature of their diabetes, these patients are at much higher risk of complications from seemingly benign infections as well as increasingly susceptible to more resistant or invasive disease. Targeted prevention where possible, regular follow-up, and early, aggressive treatment are crucial to diabetic patients’ longevity and quality of life. This review will focus on key vaccine-preventable issues as well as management of common conditions such as urinary tract infection and skin and soft tissue infection often seen in diabetic patients.

OPINION PAPER: Quo vadis – EFSA?

2011 ◽  
Vol 2 (3) ◽  
pp. 177-181 ◽  
Author(s):  
G. Reid
Keyword(s):  
Quality Of Life ◽  
Infectious Disease ◽  
Disease Management ◽  
Human Life ◽  
Medical Studies ◽  
Good Science ◽  
Vaginal Health ◽  
Alternative Approaches ◽  
Quo Vadis

In times when human life and quality of life remain threatened by infectious diseases, increasing microbial resistance and a diminished armamentarium of treatments, you might think that the European Commission would urgently seek and encourage alternative approaches. On the contrary, the European Food Safety Authority (EFSA) has created a panel that has ignored good science, over-ridden peer-reviewed medical studies, and seems intent on breaking the back of a validated approach to infectious disease management, namely probiotics. The recent rejection of a simple and quite bland claim related to vaginal health emphasises the travesty of this bureaucracy. Herein, the science fights back and counters the critique of EFSA.

scholarly journals 811. A Randomized Controlled Trial of Prednisolone vs. Interleukin 17 A Inhibitor Secuinumab in the Management of Type 1 Lepra Reaction in Leprosy Patients

2018 ◽  
Vol 5 (suppl_1) ◽  
pp. S290-S290 ◽  
Author(s):  
Debdeep Mitra
Keyword(s):  
Quality Of Life ◽  
Infectious Disease ◽  
Adverse Events ◽  
Short Form ◽  
Clinical Severity ◽  
Interleukin 17 ◽  
Randomized Control ◽  
Hands And Feet

Abstract Background Leprosy is a chronic granulomatous infectious disease caused by Mycobacterium leprae. Type 1 lepra reactions (T1R) are delayed hypersensitivity (Type IV) reactions which if not treated promptly leads to disability affecting eyes, hands and feet. IL-17 A which is produced mainly by inflammatory T helper 17 cells is up regulated in patients of Lepra reaction. Conventionally oral corticosteroids steroids have been the main stay in the management of Type 1 lepra reactions. This novel biologic drug is a targeted therapy which blocks the offending interleukin molecule without any serious adverse effects. We report the results of this randomized control study wherein an immuno-modulator biologic molecule has been safely used to treat an inflammatory reaction in a chronic infectious disease. Outcomes were measured using recurrence rate, a clinical severity score, quality of life, and adverse events. Methods Seventy-four patients with new T1R were randomized to receive Secukinumab (a human IgG1κ monoclonal antibody that binds to the protein interleukin (IL)-17A) or Prednisolone for 20 weeks. IL-17 A levels were correlated before and after the intervention. Results Recovery rates in skin signs was similar in both groups (92% vs. 87%). Improvements in nerve function both, new and old, sensory (67% vs. 48%) and motor (73% vs. 76%) loss were higher (but not significantly so) in the patients on Secukinumab. Recurrences rates of lepra reaction (25%) were high in both groups, and recurrences occurred significantly earlier (8 weeks) in patients on Secukinumab, who needed 10% more additional prednisolone. Serious major and minor adverse events rates were much lesser with Secukinumab as compared with Prednisolone alone. Both groups had a significant improvement in their quality of life after the study, measured by the Short form survey SF-36. Conclusion This is the first double-blind randomized control trial assessing Secukinumab, in the management of lepra reaction. It could be a safe alternative second-line drug for patients with leprosy reactions who are not improving with prednisolone or are experiencing adverse events related to prednisolone. IL-17A levels could be an important diagnostic marker to diagnose and prognosticate cases of Type 1 Lepra reaction, which if not treated in time can lead to irreversible nerve damage. Disclosures All authors: No reported disclosures.

Sign in / Sign up

Export Citation Format

Share Document